These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21514303)

  • 1. Structural basis for Streptococcus pneumoniae NanA inhibition by influenza antivirals zanamivir and oseltamivir carboxylate.
    Gut H; Xu G; Taylor GL; Walsh MA
    J Mol Biol; 2011 Jun; 409(4):496-503. PubMed ID: 21514303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay.
    Quosdorf S; Schuetz A; Kolodziej H
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29149072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).
    Hitaoka S; Matoba H; Harada M; Yoshida T; Tsuji D; Hirokawa T; Itoh K; Chuman H
    J Chem Inf Model; 2011 Oct; 51(10):2706-16. PubMed ID: 21870866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
    Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
    Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
    Kongkamnerd J; Cappelletti L; Prandi A; Seneci P; Rungrotmongkol T; Jongaroonngamsang N; Rojsitthisak P; Frecer V; Milani A; Cattoli G; Terregino C; Capua I; Beneduce L; Gallotta A; Pengo P; Fassina G; Miertus S; De-Eknamkul W
    Bioorg Med Chem; 2012 Mar; 20(6):2152-7. PubMed ID: 22342267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999.
    Bauer K; Schrader C; Suess J; Wutzler P; Schmidtke M
    Antiviral Res; 2007 Sep; 75(3):219-26. PubMed ID: 17445913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
    Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
    Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
    Wang SQ; Du QS; Chou KC
    Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The war against influenza: discovery and development of sialidase inhibitors.
    von Itzstein M
    Nat Rev Drug Discov; 2007 Dec; 6(12):967-74. PubMed ID: 18049471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
    Hurt AC; Lowther S; Middleton D; Barr IG
    Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
    Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
    Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host.
    Trappetti C; Kadioglu A; Carter M; Hayre J; Iannelli F; Pozzi G; Andrew PW; Oggioni MR
    J Infect Dis; 2009 May; 199(10):1497-505. PubMed ID: 19392624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.
    Sheu TG; Deyde VM; Garten RJ; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):354-60. PubMed ID: 19887086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
    Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
    J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
    Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
    Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
    Wang YT; Chan CH; Su ZY; Chen CL
    Biophys Chem; 2010 Mar; 147(1-2):74-80. PubMed ID: 20045243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.
    Ferraris O; Kessler N; Valette M; Lina B
    Vaccine; 2006 Nov; 24(44-46):6656-9. PubMed ID: 16797804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.